Dogwood Therapeutics, Inc. Common StockDWTX
About: Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM) and Long-COVID (LC). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
Employees: 4
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
0% more funds holding
Funds holding: 24 [Q2] → 24 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
16% less capital invested
Capital invested by funds: $215K [Q2] → $180K (-$34.8K) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for DWTX.
Financial journalist opinion
We haven’t received any recent news articles for DWTX.